Page last updated: 2024-12-06

benzoctamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzoctamine is a muscle relaxant that acts on the central nervous system. It is a synthetic compound chemically related to benzodiazepines, but it does not have significant anxiolytic or hypnotic properties. Benzoctamine is primarily used to treat muscle spasms and pain caused by various conditions such as multiple sclerosis, cerebral palsy, and spinal cord injuries. Its mechanism of action is believed to involve modulation of GABAergic neurotransmission and suppression of neuronal excitability. Benzoctamine has been studied for its potential therapeutic benefits in conditions like spasticity, neuropathic pain, and even alcohol withdrawal syndrome. Research interest in benzoctamine stems from its unique pharmacological profile, which combines muscle relaxant effects with relatively limited sedation and dependence liability. However, its use is relatively limited due to potential side effects such as dizziness, drowsiness, and gastrointestinal disturbances. Further research is ongoing to explore its clinical applications and optimize its therapeutic use.'

benzoctamine: minor descriptor (72); major descriptor (73-86); on line search ANTHRACENES (72-86); INDEX MEDICUS search ANTHRACENES (72); BENZOCTAMINE (73-86) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID28425
CHEMBL ID2110603
CHEBI ID135017
SCHEMBL ID115617
MeSH IDM0263164

Synonyms (35)

Synonym
17243-39-9
1-(9,10-ethanoanthracen-9(10h)-yl)-n-methylmethanamine
benzoktamina [polish]
benzoctamina [inn-spanish]
ethanoanthracene-9(10h)-methylamine, n-methyl-
benzoctamine [inn:ban]
brn 2811058
benzoctaminum [inn-latin]
9,10-ethanoanthracene-9(10h)-methanamine, n-methyl-
benzoctamine
9,10-ethanoanthracene-9(10h)-methylamine, n-methyl-, 9,10-dihydro
CHEBI:135017
n-methyl-9,10-ethanoanthracene-9(10h)-methanamine
9,10-ethanoanthracene-9(10h)-methylamine, n-methyl-
734mm7y191 ,
benzoktamina
unii-734mm7y191
benzoctaminum
benzoctamina
benzoctamine [mi]
n-methyl-9,10-ethanoanthracene-9(10h)-methylamine
benzoctamine [who-dd]
benzoctamine [inn]
SCHEMBL115617
CHEMBL2110603
n-methyl-9,10-ethanoantrhacene-9(10h)-methylamine
GNRXCIONJWKSEA-UHFFFAOYSA-N
DTXSID4022654
1-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-n-methylmethanamine
DB09021
Q4890786
n-methyl-1-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)methanamine
9-(methylaminomethyl)-9,10-dihydro-9,10-ethanoanthracene
HY-A0171
SB81277
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (72.73)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.09 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other7 (58.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]